B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

SCN9A

MOLECULAR TARGET

sodium voltage-gated channel alpha subunit 9

UniProt: Q15858NCBI Gene: 633514 compounds

SCN9A (sodium voltage-gated channel alpha subunit 9) is targeted by 14 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting SCN9A

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1carbamazepine5.34208
2mibefradil4.2670
3safinamide4.1361
4mexiletine3.9953
5tetrodotoxin3.1422
6pf 050897712.4010
7mexiletine hydrochloride1.956
8Lacosamide0.691
9Lidocaine0.691
10Saxitoxin0.691
11Veratridine0.691
12bdb n 7 3r 5r 7r adamantan 1 ylmethoxy 6 cyclopropyl 1 2 4 triazolo 4 3 a pyridin 3 0.691
13bdb n 7 adamantan 1 ylmethoxy 6 ethyl 1 2 4 triazolo 4 3 a pyridin 3 yl cyclopropane0.691
14bdb chembl44470210.691

About SCN9A as a Drug Target

SCN9A (sodium voltage-gated channel alpha subunit 9) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 14 compounds with documented SCN9A interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

SCN9A inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.